Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

H Kazancioglu; Gulsum Ak

EN TR

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Abstract

Hemofili A erkek bebeklerin 1/5000’ini etkileyen en yaygın kalıtımsal koagülasyon bozukluğudur. Hemofili A hastalarının %25-30’unda, Hemofili B hastalarının ise %1-3’ünde yaşamları boyunca inhibitör gelişebilir. İnhibitör gelişen hemofili hastalarını tedavilerini yapmanın en etkili yol ise bu hastalara rekombinant faktör VIIa uygulanmasıdır. FVIIa plazmada pıhtının erime zamanını uzatır ve trombin ile aktive olabilen fibrinolizis inhibitörü yolu ile fibrinolizisi azaltır. Bu makalede faktör VIII’e karşı aşırı inhibitör gelişen bir hemofili hastasının yapılan başarılı dental tedavisini anlattık. rFVIIa’nın geleneksel tedavilere(örneğin faktör konsantresi) göre avantajları antijenitesinin olmaması ve viral güvenliğidir. Ancak geleneksel yöntemlere göre daha pahalı bir tedavi yöntemidir.

Keywords

-

References

Müftüoğlu E. Klinik Hematoloji. 4. Baskı. Diyarbakır: Şahin Yayıncılık 1995;561-7.
Caglar K, Cetinkaya A, Aytac S. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia ; 8: 322-29. Wilde JT. HIV and HCV coinfection in haemophilia. Haemophilia 2004; 10:1-8.
Bump RL, Kolodny SC. Fibrinoliysis: A possible factor in the control of postoperative hemorrhage in the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1973; 36: 195-200.
Borea G, Hontebugnoli L, Capuzzi P, Magelli G. Tranexamic acid as a mouthwash in anticoagulant treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993; 75: 29-31.
Eastmen JR, Nowakowski AR, Triplett DA. DDAVP: review of indicators for its use in the treatment of factor VIII deficiency and report of a case. Oral Surg Oral Med Oral Pathol 1983; 56: 246-51.
Racocz M, Mazar A, Varo D, Spierer S. Dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol 1993; 75: 280-82.
Katz JO, Terezhalmy GT. Dental management of the patient with haemophilia. Oral Surg Oral Med Oral Pathol 1988; 66: 139-44.

Manucci PH. Desmopressin (DDAVP) in the treatment of blleedin disorders: first 20 years. Blood ; 90: 2515-21.
Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deaminocys-8-D-argine-vasopressin) treatment in children with haemophilia B. Brit J Haemathol 2000; 111: 1260-62.
Piot B, Sigaud M, Huet P, Fressinaud E, Trossa M, Mercier J. Management of dental extractions in patient with bleeding disorders. Oral Surg Oral Med Oral Pathol 2002; 93: 247-50.
High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995:79-86.
Hoyer LW. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White CG, eds. Inhibitors to Coagulation Factors. New York: Plenum Press; 1995: 35-45.
Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 39.
Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost ; 26: 425-32. Lund-Hansen Haemostasis. 1996; 26: 96-97.
Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 407-12.
Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998; 9: –23.
Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. 2450/2008.0015-08. NovoSeven—virus safety. Blood Transfus ;7:24-8. DOI
Midathada MV, Mehta P, Waner M, Fink LM. Recombinant Factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004;121:124-137.
Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42.
Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-47.
Laguna P, Klukowska A. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor. Haemophilia 2005; 11: 2
Shapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22–38.
Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912–8.
Millar CG, Stringer MD, Sugarman I, Richards M. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171–74.
Janic D, Brdar R, Kristic Z, Jovanovic N, Dokmanovic L, Rodic P, Petronic I, Antovic J. Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa. Haemophilia 2007; 13: 214–

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

H Kazancioglu

Gulsum Ak

Publication Date

January 5, 2011

Submission Date

January 5, 2011

Acceptance Date

-

Published in Issue

Year 2010 Volume: 13 Number: 2

IZ

https://izlik.org/JA27GK66AZ

Cite

RIS / Bibtex

EndNote

Kazancioglu H, Ak G (January 1, 2011) Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı. Cumhuriyet Dental Journal 13 2 101–105.

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Abstract

Keywords

Faktör VIII’e Karşı İnhibitör Gelişen Hemofili Hastalarında Dental Tedavi Yaklaşımı

Öz

Anahtar Kelimeler

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

IZ

Cite